Indian Patent Office rejects Pfizer’s arthritis patent, again

08-09-2015

Indian Patent Office rejects Pfizer’s arthritis patent, again

360b / Shutterstock.com

Pfizer has had a patent application for tofacitinib, which is marketed as Xeljanz and Jakvinus, rejected by the Indian Patent Office (IPO) for the second time.


Pfizer; Indian Patent Office; IPAB; tofacitinib; Xeljanz; Jakvinus

LSIPR